000912505 001__ 912505
000912505 005__ 20230123110757.0
000912505 0247_ $$2doi$$a10.1016/j.jocn.2022.05.031
000912505 0247_ $$2ISSN$$a0967-5868
000912505 0247_ $$2ISSN$$a1532-2653
000912505 0247_ $$2Handle$$a2128/33084
000912505 0247_ $$2pmid$$a35687921
000912505 0247_ $$2WOS$$aWOS:000833364000002
000912505 037__ $$aFZJ-2022-05678
000912505 082__ $$a610
000912505 1001_ $$0P:(DE-HGF)0$$aFervers, Philipp$$b0$$eCorresponding author
000912505 245__ $$aMeaningful use of imaging resources to rule out cerebral venous sinus thrombosis after ChAdOx1 COVID-19 vaccination: Evaluation of the AHA diagnostic algorithm with a clinical cohort and a systematic data review
000912505 260__ $$aBurlington, Mass.$$bHarcourt$$c2022
000912505 3367_ $$2DRIVER$$aarticle
000912505 3367_ $$2DataCite$$aOutput Types/Journal article
000912505 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1670935283_32695
000912505 3367_ $$2BibTeX$$aARTICLE
000912505 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000912505 3367_ $$00$$2EndNote$$aJournal Article
000912505 520__ $$aVaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous thrombosis (CVST) is an improbable (0.0005%), however potentially lethal complication after ChAdOx1 vaccination. On the other hand, headache is among the most frequent side effects of ChAdOx1 (29.3%). In September 2021, the American Heart Association (AHA) suggested a diagnostic workflow to facilitate risk-adapted use of imaging resources for patients with neurological symptoms after ChAdOx1. We aimed to evaluate the AHA workflow in a retrospective patient cohort presenting at four primary care hospitals in Germany for neurological complaints after ChAdOx1. Scientific literature was screened for case reports of VITT with CVST after ChAdOx1, published until September 1st, 2021. One-hundred-thirteen consecutive patients (77 female, mean age 38.7 +/− 11.9 years) were evaluated at our institutes, including one case of VITT with CVST. Further 228 case reports of VITT with CVST are published in recent literature, which share thrombocytopenia (225/227 reported) and elevated d-dimer levels (100/101 reported). The AHA workflow would have recognized all VITT cases with CVST (100% sensitivity), the number needed to diagnose (NND) was 1:113. Initial evaluation of thrombocytopenia or elevated d-dimer levels would have lowered the NND to 1:68, without cost of sensitivity. Hence, we suggest that in case of normal thrombocyte and d-dimer levels, the access to further diagnostics should be limited by the established clinical considerations regardless of vaccination history.
000912505 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000912505 588__ $$aDataset connected to DataCite
000912505 7001_ $$0P:(DE-HGF)0$$aKottlors, Jonathan$$b1
000912505 7001_ $$0P:(DE-HGF)0$$aPersigehl, Thorsten$$b2
000912505 7001_ $$0P:(DE-HGF)0$$aLennartz, Simon$$b3
000912505 7001_ $$0P:(DE-HGF)0$$aMaus, Volker$$b4
000912505 7001_ $$0P:(DE-Juel1)192547$$aFischer, Sebastian$$b5$$ufzj
000912505 7001_ $$0P:(DE-HGF)0$$aStyczen, Hanna$$b6
000912505 7001_ $$0P:(DE-HGF)0$$aDeuschl, Cornelius$$b7
000912505 7001_ $$0P:(DE-HGF)0$$aSchlamann, Marc$$b8
000912505 7001_ $$0P:(DE-HGF)0$$aMpotsaris, Anastasios$$b9
000912505 7001_ $$0P:(DE-HGF)0$$aZubel, Seraphine$$b10
000912505 7001_ $$0P:(DE-HGF)0$$aSchroeter, Michael$$b11
000912505 7001_ $$0P:(DE-HGF)0$$aMaintz, David$$b12
000912505 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon Rudolf$$b13$$ufzj
000912505 7001_ $$0P:(DE-HGF)0$$aAbdullayev, Nuran$$b14
000912505 773__ $$0PERI:(DE-600)2009190-4$$a10.1016/j.jocn.2022.05.031$$gVol. 102, p. 5 - 12$$p5 - 12$$tJournal of clinical neuroscience$$v102$$x0967-5868$$y2022
000912505 8564_ $$uhttps://juser.fz-juelich.de/record/912505/files/PDF.pdf$$yOpenAccess
000912505 909CO $$ooai:juser.fz-juelich.de:912505$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000912505 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)192547$$aForschungszentrum Jülich$$b5$$kFZJ
000912505 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b13$$kFZJ
000912505 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000912505 9141_ $$y2022
000912505 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000912505 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000912505 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000912505 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-17$$wger
000912505 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000912505 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000912505 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000912505 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN NEUROSCI : 2021$$d2022-11-17
000912505 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000912505 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-17
000912505 920__ $$lyes
000912505 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000912505 980__ $$ajournal
000912505 980__ $$aVDB
000912505 980__ $$aUNRESTRICTED
000912505 980__ $$aI:(DE-Juel1)INM-3-20090406
000912505 9801_ $$aFullTexts